These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 23103197)
1. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Fox CB; Huynh C; O'Hara MK; Onu A Vaccine; 2013 Mar; 31(12):1633-40. PubMed ID: 23103197 [TBL] [Abstract][Full Text] [Related]
2. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Ventura R; Brunner L; Heriyanto B; de Boer O; O'Hara M; Huynh C; Suhardono M; Collin N Vaccine; 2013 Mar; 31(12):1641-5. PubMed ID: 22884665 [TBL] [Abstract][Full Text] [Related]
3. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392 [TBL] [Abstract][Full Text] [Related]
4. An international technology platform for influenza vaccines. Hendriks J; Holleman M; de Boer O; de Jong P; Luytjes W Vaccine; 2011 Jul; 29 Suppl 1():A8-11. PubMed ID: 21684431 [TBL] [Abstract][Full Text] [Related]
5. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Friede M; Palkonyay L; Alfonso C; Pervikov Y; Torelli G; Wood D; Kieny MP Vaccine; 2011 Jul; 29 Suppl 1():A2-7. PubMed ID: 21684422 [TBL] [Abstract][Full Text] [Related]
6. Development of pandemic influenza vaccine production capacity in Viet Nam. Hoa LK; Hiep LV; Be LV Vaccine; 2011 Jul; 29 Suppl 1():A34-6. PubMed ID: 21684426 [TBL] [Abstract][Full Text] [Related]
7. The Vaccine Formulation Laboratory: a platform for access to adjuvants. Collin N; Dubois PM Vaccine; 2011 Jul; 29 Suppl 1():A37-9. PubMed ID: 21684427 [TBL] [Abstract][Full Text] [Related]
8. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Miyaki C; Meros M; Precioso AR; Raw I Vaccine; 2011 Jul; 29 Suppl 1():A12-5. PubMed ID: 21684420 [TBL] [Abstract][Full Text] [Related]
9. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428 [TBL] [Abstract][Full Text] [Related]
10. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
11. Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative. Grohmann G; Francis DP; Sokhey J; Robertson J Vaccine; 2016 Oct; 34(45):5420-5424. PubMed ID: 27506497 [TBL] [Abstract][Full Text] [Related]
12. A pandemic influenza vaccine in India: from strain to sale within 12 months. Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421 [TBL] [Abstract][Full Text] [Related]
13. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Perdue ML; Bright RA Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430 [TBL] [Abstract][Full Text] [Related]
14. WHO influenza vaccine technology transfer initiative: role and activities of the Technical Advisory Group. Francis DP; Grohmann G Vaccine; 2011 Jul; 29 Suppl 1():A45-7. PubMed ID: 21684429 [TBL] [Abstract][Full Text] [Related]
15. Vaccine production training to develop the workforce of foreign institutions supported by the BARDA influenza vaccine capacity building program. Tarbet EB; Dorward JT; Day CW; Rashid KA Vaccine; 2013 Mar; 31(12):1646-9. PubMed ID: 22749796 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive hands-on training for influenza vaccine manufacturing: a WHO-BARDA-BTEC partnership for global workforce development. Ruiz J; Gilleskie GL; Brown P; Burnett B; Carbonell RG Biochem Mol Biol Educ; 2014; 42(5):414-9. PubMed ID: 25132407 [TBL] [Abstract][Full Text] [Related]
17. [Influenza vaccine: globalization of public health stakes]. Collin N; Briand S Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377 [TBL] [Abstract][Full Text] [Related]
19. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia. Suhardono M; Ugiyadi D; Nurnaeni I; Emelia I Vaccine; 2011 Jul; 29 Suppl 1():A22-5. PubMed ID: 21684423 [TBL] [Abstract][Full Text] [Related]